-   Training & Support

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised brentuximab vedotin and
pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma
(HL) and who have failed autologous stem cell transplant (ASCT) or are
ASCT naïve.

HL and listing dates

HL is a cancer of the immune system.

Listing dates:

-   brentuximab vedotin- 1 April 2017
-    pembrolizumab - 1 May 2018

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Tier 0 technical support - self-sufficiency

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Process written authority approval requests

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Work Optimiser for staff

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
